CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.
"The CytoGenix synDNA™ technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron.
"One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA."
Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA."
"We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA™."